New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Kura Oncology, Inc.

Contributing Author

Recent Articles by Kura Oncology, Inc.

Sep-16	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types KURA GlobeNewswire
Sep-05	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Sep-03	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program KURA GlobeNewswire
Aug-28	Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
Aug-07	Kura Oncology Reports Second Quarter 2025 Financial Results KURA GlobeNewswire
Aug-04	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jul-31	Kura Oncology to Report Second Quarter 2025 Financial Results KURA GlobeNewswire
Jul-03	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-12	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress KURA GlobeNewswire
Jun-06	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-02	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting KURA GlobeNewswire
Jun-01	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML KURA GlobeNewswire
May-22	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting KURA GlobeNewswire
May-20	Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
May-14	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress KURA GlobeNewswire
May-06	Kura Oncology to Participate in Bank of America Securities Healthcare Conference KURA GlobeNewswire
May-02	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
May-01	Kura Oncology Reports First Quarter 2025 Financial Results KURA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.